BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 241 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.25 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,527,717 | +298.4% | 780,751 | +296.2% | 0.01% | +250.0% |
| Q2 2023 | $1,387,436 | +311.3% | 197,079 | +387.3% | 0.00% | -20.0% |
| Q1 2023 | $337,303 | -95.7% | 40,444 | -94.1% | 0.01% | -96.5% |
| Q4 2022 | $7,826,295 | +86.7% | 681,733 | +104.8% | 0.14% | +78.8% |
| Q3 2022 | $4,193,000 | +564.5% | 332,814 | +458.4% | 0.08% | +370.6% |
| Q2 2022 | $631,000 | -78.7% | 59,598 | -67.4% | 0.02% | -78.5% |
| Q1 2022 | $2,969,000 | +402.4% | 182,567 | +343.9% | 0.08% | +364.7% |
| Q3 2021 | $591,000 | +167.4% | 41,131 | +194.7% | 0.02% | +112.5% |
| Q2 2021 | $221,000 | -29.4% | 13,958 | -91.1% | 0.01% | -88.4% |
| Q1 2020 | $313,000 | -12.3% | 156,507 | +51.4% | 0.07% | +200.0% |
| Q4 2019 | $357,000 | – | 103,350 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burrage Capital Management LLC | 864,916 | $13,674,000 | 13.71% |
| Sarissa Capital Management LP | 4,261,000 | $67,366,000 | 5.36% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,920,733 | $30,367,000 | 4.18% |
| HealthCor Management, L.P. | 3,248,100 | $51,352,000 | 2.05% |
| Parkman Healthcare Partners LLC | 351,961 | $5,565,000 | 1.22% |
| Bain Capital Public Equity Management II, LLC | 1,560,730 | $24,675,000 | 1.06% |
| Baker Brothers Advisors | 12,710,818 | $200,958,000 | 0.88% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,835,000 | $44,821,000 | 0.80% |
| Biondo Investment Advisors, LLC | 265,840 | $4,203,000 | 0.72% |
| EAM Global Investors LLC | 157,065 | $2,483,000 | 0.69% |